132
The Technical Scientific Commission (CTS) of AIFA has approved the extension of indication of use of the Spikevax (Moderna) vaccine for the age group between 12 and 17 years, fully accepting the opinion expressed by the European Medicines Agency (EMA ). According to the CTS, in fact, the available data demonstrate the efficacy and safety of the vaccine even for subjects included in this age group.
breaking latest news © Copyright ANSA